Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Active, not recruiting · NCT05502315 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-09-08 | NCT05502315 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Exelixis | 77 |
| Rana McKay, MD | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California San Diego | La Jolla | United States | 54 |
| University of Chicago Medical Center | Chicago | United States | 152 |
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |
| University of Wisconsin | Madison | United States | 64 |